Literature DB >> 8823689

Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus.

F Fawaz-Estrup1.   

Abstract

OBJECTIVE: To investigate the clinical and serological characteristics of parvovirus infection. CASE SERIES: during 1993-4, 9 adult patients presented with polyarthralgias/polyarthritis. Clinical evaluation and serological studies of antinuclear antibodies, rheumatoid factor (RF), IgM and IgG antibodies to human parvovirus were done in all patients. Other serologies including anti-DNA, serum complement, and C1 esterase inhibitor levels were obtained in some patients.
RESULTS: All 9 patients had polyarthralgias/polyarthritis, serological evidence of parvovirus B19 IgM and IgG antibodies, and normal sedimentation rate. All patients were seronegative for RF. Four women had positive ANA titers. In 2 of them the ANA positivity was transient. One developed systemic lupus erythematosus (SLE). Three women had angioedema of the face and tongue; one had transient C1 esterase inhibitor deficiency and another a transient decrease in C4 levels.
CONCLUSION: Parvovirus may be implicated in the development of SLE as well as other chronic arthropathies. This is the first reported case of angioedema and decreased C1 esterase inhibitor levels associated with parvovirus infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823689

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis.

Authors:  Sarah Bradshaw; W Jim Zheng; Lam C Tsoi; Gary Gilkeson; Xian K Zhang
Journal:  Clin Immunol       Date:  2008-08-09       Impact factor: 3.969

Review 2.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 3.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

4.  The relationship between arthritis and human parvovirus B19 infection.

Authors:  R Caliskan; S Masatlioglu; M Aslan; S Altun; S Saribas; S Ergin; E Uckan; V Koksal; V Oz; K Altas; I Fresko; B Kocazeybek
Journal:  Rheumatol Int       Date:  2004-08-20       Impact factor: 2.631

5.  Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells.

Authors:  T-C Hsu; B-S Tzang; C-N Huang; Y-J Lee; G-Y Liu; M-C Chen; G J Tsay
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

6.  Socks but no gloves.

Authors:  N Cimolai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

Review 7.  Systemic lupus erythematosus and parvovirus B-19: casual coincidence or causative culprit?

Authors:  Marianne C Severin; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

8.  Middle cerebral artery thrombosis in course of parvovirus B19 infection in a young adult: A new risk factor for stroke?

Authors:  Jessica Mandrioli; Marinella Portolani; Pietro Cortelli; Patrizia Sola
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

9.  Parvovirus B19-related chronic monoarthritis: immunohistochemical detection of virus-positive lymphocytes within the synovial tissue compartment: two reported cases.

Authors:  Carsten Lennerz; Henning Madry; Sandra Ehlhardt; Thorsten Venzke; Klaus D Zang; Yasmin Mehraein
Journal:  Clin Rheumatol       Date:  2003-11-05       Impact factor: 3.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.